MX2016013108A - Nueva composicion para el tratamiento de la tricomoniasis. - Google Patents

Nueva composicion para el tratamiento de la tricomoniasis.

Info

Publication number
MX2016013108A
MX2016013108A MX2016013108A MX2016013108A MX2016013108A MX 2016013108 A MX2016013108 A MX 2016013108A MX 2016013108 A MX2016013108 A MX 2016013108A MX 2016013108 A MX2016013108 A MX 2016013108A MX 2016013108 A MX2016013108 A MX 2016013108A
Authority
MX
Mexico
Prior art keywords
treatment
trichomoniasis
new composition
compositions
compounds
Prior art date
Application number
MX2016013108A
Other languages
English (en)
Inventor
Ordaz Pichardo Cynthia
Arroyo Verástegui Rossana
Ortega López Jaime
Guadalupe BENÍTEZ CARDOZA Claudia
Luis VIQUE SÁNCHEZ José
Gabriel Brieba De Castro Luis
Rojo Domínguez Arturo
GARCÍA GUTIÉRREZ Ponciano
Original Assignee
Inst Politecnico Nacional
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Politecnico Nacional filed Critical Inst Politecnico Nacional
Priority to MX2016013108A priority Critical patent/MX2016013108A/es
Priority to PCT/IB2016/056003 priority patent/WO2018065809A1/es
Publication of MX2016013108A publication Critical patent/MX2016013108A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe composiciones farmacéuticas útiles para el tratamiento de tricomoniasis que comprenden compuestos con la estructura química (ver Fórmulas) las cuales también exhiben efecto sinérgico y no presentan los efectos adversos típicos de compuestos utilizados comúnmente en el tratamiento de dicha enfermedad, tales como por ejemplo metronidazol.
MX2016013108A 2016-10-06 2016-10-06 Nueva composicion para el tratamiento de la tricomoniasis. MX2016013108A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2016013108A MX2016013108A (es) 2016-10-06 2016-10-06 Nueva composicion para el tratamiento de la tricomoniasis.
PCT/IB2016/056003 WO2018065809A1 (es) 2016-10-06 2016-10-07 Nueva composición para el tratamiento de la tricomoniasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016013108A MX2016013108A (es) 2016-10-06 2016-10-06 Nueva composicion para el tratamiento de la tricomoniasis.

Publications (1)

Publication Number Publication Date
MX2016013108A true MX2016013108A (es) 2018-04-05

Family

ID=61832083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013108A MX2016013108A (es) 2016-10-06 2016-10-06 Nueva composicion para el tratamiento de la tricomoniasis.

Country Status (2)

Country Link
MX (1) MX2016013108A (es)
WO (1) WO2018065809A1 (es)

Also Published As

Publication number Publication date
WO2018065809A1 (es) 2018-04-12

Similar Documents

Publication Publication Date Title
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
WO2015120062A3 (en) Therapeutic compounds and compositions
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12016501807A1 (en) Novel compounds
MX2017007188A (es) Compuesto antimicotico.
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
PH12017501133A1 (en) Pyrazolopyridinamines
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
GB2564990A8 (en) Topical compositions for neuropathic pain
WO2016020408A3 (en) Compounds for preventing ototoxicity
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.